The development of malignancy may be linked to the use of immunomodulators. Data suggests that the risks of overall, breast, or lung malignancies are not significantly increased in patients treated with abatacept . These findings are consistent with the established safety profile of abatacept.
Patients with rheumatoid arthritis (RA) are at an increased risk of malignancies compared with the general population . Abatacept is a biologic immune modulator for RA, selectively blocking the specific interaction of CD80/CD86 receptors to CD28 and, therefore, inhibiting T cell proliferation and B cell immunological response. Abatacept has demonstrated efficacy and safety in the treatment of RA. “We have observed that, in clinical trial data, malignancy rates are similar for abatacept compared with placebo-treated patients and that post-marketing observational studies are valuable to assess the long-term risk associated with the medication,” said Dr Teresa Sim...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Switching among multiple infliximab biosimilars does not cause immunogenicity Next Article
Preliminary Efficacy and Safety Data of RG6125 in RA Patients with an Inadequate Response to TNF Inhibitors »
Table of Contents: EULAR 2019
Osteoarthritis and Osteoporosis
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.